We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
63
6 active
Approvals
10
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Active, not recruiting
2
3.2%
Completed
38
60.3%
Not yet recruiting
4
6.3%
Recruiting
1.6%
Terminated
NMPA
National Medical Products Administration
- Japan's MHLW approved XEOMIN® (incobotulinumtoxinA) for cervical dystonia and blepharospasm, marking the fourth and fifth indications for the drug in Japan. - The approval was supported by Phase III trials conducted globally by Merz Therapeutics and locally by Teijin Pharma, including a 48-week Japanese blepharospasm study. - An estimated 28,000 people in Japan suffer from blepharospasm, with tens of thousands more affected by cervical dystonia, representing significant unmet need. - XEOMIN®'s purified formulation, free of complexing proteins, may reduce the risk of neutralizing antibody development during long-term repeat dosing.
